{
  "slug": "advanced-accelerator-applications",
  "name": "Advanced-accelerator-applications",
  "description": "Advanced Accelerator Applications, an entity within Novartis, develops radioligand therapies (RLTs), a novel precision medicine approach for cancer care that combines a targeting compound with a radioisotope to find, diagnose, and treat cancer cells throughout the body while minimizing harm to healthy cells.",
  "url": "https://optimly.ai/brand/advanced-accelerator-applications",
  "websiteUrl": "https://novartis.com/",
  "logoUrl": "https://logo.clearbit.com/novartis.com",
  "baiScore": null,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": null,
  "archetype_status": "active",
  "category": "Radioligand Therapies",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-08-23T00:05:36.917Z",
  "verifiedVitals": {
    "website": "https://novartis.com",
    "category": "Pharmaceuticals, Oncology",
    "what_it_does": "Develops, produces, and provides radioligand therapies (RLTs) for cancer care, including diagnostic imaging and therapeutic applications. It also supports healthcare system readiness for RLTs by optimizing treatment centers, diagnostic capacity, infrastructure, personnel training, radiosafety, regulatory frameworks, and referral pathways.",
    "primary_audience": "Healthcare professionals, patients with cancer (including prostate and neuroendocrine tumors), and healthcare systems.",
    "core_product": "Radioligand therapies (RLTs)",
    "pricing_model": null,
    "parent_ownership": "Novartis"
  },
  "intentTags": null,
  "businessProfileClaims": [],
  "timestamp": 1787463039301
}